Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135902 · ClinicalTrials.gov registry record · Phase 3
Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies
A Phase 3 study, sponsored by The George Washington University Biostatistics Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT00135902 is a Phase 3 study that has completed, run by The George Washington University Biostatistics Center. The registered enrollment target is 800 participants.
The verdict
NCT00135902, a Phase 3 study, has completed, sponsored by The George Washington University Biostatistics Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
A recently completed trial of weekly injections of 17 alpha hydroxyprogesterone caproate (17P) found significant effectiveness for 17P in preventing recurrent preterm birth. However, the group who received 17P in this trial still had a high rate of preterm birth. Several reports have shown that dietary supplementation of fish oil, which is rich in Omega-3 fatty acids, reduces the risk of preterm birth. This trial tests whether adding the Omega-3 supplement to 17P therapy has the potential for further reducing the risk of preterm birth in women who have previously had a spontaneous preterm delivery. The trial will compare Omega-3 fatty acid with placebo in women receiving 17P therapy. The hypothesis being tested is: "Among women at high risk for preterm birth receiving weekly injections of 17P, the addition of Omega-3 nutritional supplement will further reduce the rate of preterm birth."
Interventions
- DRUG 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement
- DRUG 17 alpha-hydroxy progesterone caproate and Placebo supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2005-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135902
The ClinicalTrials.gov registry entry for NCT00135902 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The George Washington University Biostatistics Center, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement is the first listed.
NCT00135902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135902 about?
NCT00135902 is a clinical study titled "Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies". A recently completed trial of weekly injections of 17 alpha hydroxyprogesterone caproate (17P) found significant effectiveness for 17P in preventing recurrent preterm birth. However, the group who received 17P in this trial still had a high rate of preterm birth. Several reports have shown that diet...
What is the current status of trial NCT00135902?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2005-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00135902?
The interventions under investigation include: 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement (DRUG), 17 alpha-hydroxy progesterone caproate and Placebo supplement (DRUG).
Who is sponsoring clinical trial NCT00135902?
This trial is sponsored by The George Washington University Biostatistics Center, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.